CareDx, Inc.
CDNAHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeCareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. At a $3.58B market cap, CareDx, Inc. ranks as a mid-cap company within healthcare. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
Market Cap
$3.58B
Beta
2.38
P/E (TTM)
33.27
P/E (Fwd)
53.65
EPS (TTM)
$2.08
EPS (Fwd)
$1.29
ROE
29.5%
ROA
-0.3%
Cash
$373.6M
Total Debt
$19.2M
Free CF
$112.2M
52W Change
377.0%
Annual Financials
Cash vs Debt
Where CDNA stands vs its 150-day and 200-day moving averages
As of the October 13, 2026 close, CDNA finished 87.69% above its 150-day moving average ($33.63) and 109.70% above its 200-day moving average ($30.10). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CDNA overbought or oversold?
At the October 13, 2026 close, CDNA's RSI(14) was 61.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
CareDx, Inc. holds $373.6M in cash against $19.2M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $112.2M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 29.5%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $321.8M to $379.8M.
With a beta above 1.5, CDNA tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for CareDx, Inc. and its sector.